Video

Dr. Hamstra on Length of Radiation Treatments for Patients With Prostate Cancer

Daniel A. Hamstra, MD, PhD, assistant professor of Radiation Oncology, University of Michigan Health System, discusses clinical trials comparing the length of radiation treatments for patients with prostate cancer.

Daniel A. Hamstra, MD, PhD, assistant professor of Radiation Oncology, University of Michigan Health System, discusses clinical trials comparing different lengths of radiation treatments for patients with prostate cancer.

The RTOG 0145 study compared an 8-week to 5.5-week regimen of radiation therapy in more than 1000 patients with prostate cancer, Hamstra explains. Outcomes were found to be identical regarding tumor recurrence and short- and long-term side effects, with a small increase in gastrointestinal-related effects in the longer regimen.

In the CHIP trial, more than 3000 patients from the United Kingdom were randomized to receive either an 8-week regimen, 19 treatments, or 20 treatments. In the 20-treatment arm, outcomes were reported to be similar in comparison to the 8-week regimen arm.

<<<

View more from the 2016 GU Cancer Symposium

Related Videos
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP
Hope S. Rugo, MD, FASCO, Winterhof Family Endowed Professor in Breast Cancer, professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology and Clinical Trials Education; medical director, Cancer Infusion Services; the University of California San Francisco Helen Diller Family Comprehensive Cancer Center
Virginia Kaklamani, MD, DSc, professor, medicine, Division of Hematology-Medical Oncology, The University of Texas (UT) Health Science Center San Antonio; leader, breast cancer program, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center